{"id":114694,"date":"2006-06-20T15:15:00","date_gmt":"2006-06-20T19:15:00","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/reaction-biology-corp-awarded-nih-sbir-grant-for-kinase-radioisotope-microarray-screening-development\/"},"modified":"2006-06-20T15:15:00","modified_gmt":"2006-06-20T19:15:00","slug":"reaction-biology-corp-awarded-nih-sbir-grant-for-kinase-radioisotope-microarray-screening-development","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/reaction-biology-corp-awarded-nih-sbir-grant-for-kinase-radioisotope-microarray-screening-development\/","title":{"rendered":"Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development"},"content":{"rendered":"<p class=\"s2pred\"><strong>NEWS SOURCE: Reaction Biology Corporation<\/strong><\/p>\n<p><u>ARCHIVAL CONTENT:<\/u><\/p>\n<p> MALVERN, Pa., June 20 (SEND2PRESS NEWSWIRE) &#8212; Reaction Biology Corporation (&#8220;RBC&#8221;) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC&#8217;s DiscoveryDot(TM) nanoliter screening platform. <\/p>\n<p> Protein kinase dysfunction is a key factor in cancer, inflammation and diabetes. Screening and profiling kinase inhibitors has been a major research and development effort in the pharmaceutical industry. While screening kinase activity with radioisotope detection is considered by many in the drug-discovery industry to be the &#8220;gold standard&#8221; of kinase assays, use of the format is limited by expense and the difficulty of radioactive disposal. <\/p>\n<p> The DiscoveryDot(TM) platform uses only a fraction of the reagents compared to well plate methods. &#8220;Due to our nano-scale format, the amount of radioisotope used in the process should be minimal,&#8221; said RBC Chief Technology Officer Haiching Ma, Ph.D. &#8220;This should lead to far fewer disposal and handling problems, and reduced cost overall.&#8221; <\/p>\n<p> <strong>About Reaction Biology Corporation<\/strong><\/p>\n<p> Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity. Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency. <\/p>\n<p> More information: <a href=\"http:\/\/www.reactionbiology.com\" target=\"_new\" rel=\"noopener\">http:\/\/www.reactionbiology.com<\/a><\/p>\n<p>News issued by: Reaction Biology Corporation<\/p>\n<p> # # # <\/p>\n<p><small>Original Story ID:  (1752) :: 2006-06-0620-001<\/small><\/p>\n<p><small>Original Keywords: DiscoveryDot nanoliter screening platform, RBC, genomics microarray printing technology and picoliter aerosol deposition, Reaction, Biology, Corporation, Haiching Ma Reaction Biology Corporation   <\/small><\/p>\n<p class=\"s2pred\"><strong>NEWS SOURCE: Reaction Biology Corporation<\/strong> | Published: 2006-06-20 15:15:00<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa. (SEND2PRESS NEWSWIRE) &#8212; Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC&#8217;s DiscoveryDot nanoliter screening platform.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-114694","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":519,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/114694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=114694"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/114694\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=114694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=114694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=114694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}